Limited protection against γ-herpesvirus infection by replication-deficient virus particles

References

1. Cohen JI, Mocarski ES, Raab-Traub N, Corey L, Nabel GJ. The need and challenges for development of an Epstein-Barr virus vaccine. Vaccine 2013; 31:B194–B196 [View Article][PubMed]
   [Google Scholar]
2. Young LS, Finerty S, Brooks L, Scullion F, Rickinson AB et al. Epstein-Barr virus gene expression in malignant lymphomas induced by experimental virus infection of cottontop tamarins. J Virol 1989; 63:1967–1974 [View Article][PubMed]
   [Google Scholar]
3. Thorley-Lawson DA, Hawkins JB, Tracy SI, Shapiro M. The pathogenesis of Epstein-Barr virus persistent infection. Curr Opin Virol 2013; 3:227–232 [View Article][PubMed]
   [Google Scholar]
4. Barton E, Mandal P, Speck SH. Pathogenesis and host control of gammaherpesviruses: lessons from the mouse. Annu Rev Immunol 2011; 29:351–397 [View Article][PubMed]
   [Google Scholar]
5. Gaspar M, May JS, Sukla S, Frederico B, Gill MB et al. Murid herpesvirus-4 exploits dendritic cells to infect B cells. PLoS Pathog 2011; 7:e1002346 [View Article][PubMed]
   [Google Scholar]
6. Bridgeman A, Stevenson PG, Simas JP, Efstathiou S. A secreted chemokine binding protein encoded by murine gammaherpesvirus-68 is necessary for the establishment of a normal latent load. J Exp Med 2001; 194:301–312 [View Article][PubMed]
   [Google Scholar]
7. Rice J, de Lima B, Stevenson FK, Stevenson PG. A gamma-herpesvirus immune evasion gene allows tumor cells in vivo to escape attack by cytotoxic T cells specific for a tumor epitope. Eur J Immunol 2002; 32:3481–3487 [View Article][PubMed]
   [Google Scholar]
8. Stevenson PG, Simas JP, Efstathiou S. Immune control of mammalian gamma-herpesviruses: lessons from murid herpesvirus-4. J Gen Virol 2009; 90:2317–2330 [View Article][PubMed]
   [Google Scholar]
9. van Zyl DG, Tsai M-H, Shumilov A, Schneidt V, Poirey R et al. Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice. PLoS Pathog 2018; 14:e1007464 [View Article][PubMed]
   [Google Scholar]
10. Münz C. Human γ-herpesvirus infection, tumorigenesis, and immune control in mice with reconstituted human immune system components. Front Immunol 2018; 9:238 [View Article][PubMed]
    [Google Scholar]
11. Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 1999; 190:567–576 [View Article][PubMed]
    [Google Scholar]
12. Farrell PJ. Epstein-Barr virus strain variation. Curr Top Microbiol Immunol 2015; 390:45–69 [View Article][PubMed]
    [Google Scholar]
13. Gadola SD, Moins-Teisserenc HT, Trowsdale J, Gross WL, Cerundolo V. Tap deficiency syndrome. Clin Exp Immunol 2000; 121:173–178 [View Article][PubMed]
    [Google Scholar]
14. de la Salle H, Houssaint E, Peyrat MA, Arnold D, Salamero J et al. Human peptide transporter deficiency: importance of HLA-B in the presentation of TAP-independent EBV antigens. J Immunol 1997; 158:4555–4563[PubMed]
    [Google Scholar]
15. Moser JM, Farrell ML, Krug LT, Upton JW, Speck SH. A gammaherpesvirus 68 gene 50 null mutant establishes long-term latency in the lung but fails to vaccinate against a wild-type virus challenge. J Virol 2006; 80:1592–1598 [View Article][PubMed]
    [Google Scholar]
16. Lawler C, Milho R, May JS, Stevenson PG. Rhadinovirus host entry by co-operative infection. PLoS Pathog 2015; 11:e1004761 [View Article][PubMed]
    [Google Scholar]
17. Milho R, Frederico B, Efstathiou S, Stevenson PG. A heparan-dependent herpesvirus targets the olfactory neuroepithelium for host entry. PLoS Pathog 2012; 8:e1002986 [View Article][PubMed]
    [Google Scholar]
18. Fowler P, Marques S, Simas JP, Efstathiou S. ORF73 of murine herpesvirus-68 is critical for the establishment and maintenance of latency. J Gen Virol 2003; 84:3405–3416 [View Article][PubMed]
    [Google Scholar]
19. Stevenson PG, May JS, Connor V, Efstathiou S. Vaccination against a Hit-and-run viral cancer. J Gen Virol 2010; 91:2176–2185 [View Article][PubMed]
    [Google Scholar]
20. Milho R, Smith CM, Marques S, Alenquer M, May JS et al. In vivo imaging of murid herpesvirus-4 infection. J Gen Virol 2009; 90:21–32 [View Article][PubMed]
    [Google Scholar]
21. Aricò E, Robertson KA, Belardelli F, Ferrantini M, Nash AA. Vaccination with inactivated murine gammaherpesvirus 68 strongly limits viral replication and latency and protects type I IFN receptor knockout mice from a lethal infection. Vaccine 2004; 22:1433–1440 [View Article][PubMed]
    [Google Scholar]
22. Stevenson PG, Belz GT, Castrucci MR, Altman JD, Doherty PC. A gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitope. Proc Natl Acad Sci U S A 1999; 96:9281–9286 [View Article][PubMed]
    [Google Scholar]
23. Glauser DL, Milho R, Lawler C, Stevenson PG. Antibody arrests γ-herpesvirus olfactory super-infection independently of neutralization. J Gen Virol 2019; 100:246–258 [View Article][PubMed]
    [Google Scholar]
24. Stevenson PG. Immune Control of γ-Herpesviruses. Viral Immunol 2019 [View Article][PubMed]
    [Google Scholar]
25. Lawler C, Simas JP, Stevenson PG. Vaccine protection against murid herpesvirus-4 is maintained when the priming virus lacks known latency genes. Immunol Cell Biol 2020; 98:67-7867–78 [View Article][PubMed]
    [Google Scholar]
26. Palmeira L, Sorel O, Van Campe W, Boudry C, Roels S et al. An essential role for γ-herpesvirus latency-associated nuclear antigen homolog in an acute lymphoproliferative disease of cattle. Proc Natl Acad Sci U S A 2013; 110:E1933–E1942 [View Article][PubMed]
    [Google Scholar]
27. Shivkumar M, Milho R, May JS, Nicoll MP, Efstathiou S et al. Herpes simplex virus 1 targets the murine olfactory neuroepithelium for host entry. J Virol 2013; 87:10477–10488 [View Article][PubMed]
    [Google Scholar]
28. Farrell HE, Lawler C, Tan CSE, MacDonald K, Bruce K et al. Murine cytomegalovirus exploits olfaction to enter new hosts. mBio 2016; 7:e00251 [View Article][PubMed]
    [Google Scholar]
29. E X, Meraner P, Lu P, Perreira JM, Aker AM et al. OR14I1 is a receptor for the human cytomegalovirus pentameric complex and defines viral epithelial cell tropism. Proc Natl Acad Sci U S A 2019; 116:7043–7052 [View Article][PubMed]
    [Google Scholar]
30. Okuno K, Takashima K, Kanai K, Ohashi M, Hyuga R et al. Epstein-Barr virus can infect rabbits by the intranasal or peroral route: an animal model for natural primary EBV infection in humans. J Med Virol 2010; 82:977–986 [View Article][PubMed]
    [Google Scholar]
31. Dunmire SK, Grimm JM, Schmeling DO, Balfour HH, Hogquist KA. The incubation period of primary Epstein-Barr virus infection: viral dynamics and immunologic events. PLoS Pathog 2015; 11:e1005286 [View Article][PubMed]
    [Google Scholar]
32. Tan CSE, Stevenson PG. B cell response to herpesvirus infection of the olfactory neuroepithelium. J Virol 2014; 88:14030–14039 [View Article][PubMed]
    [Google Scholar]